Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow growth accelerates
Q1 FY2026 investing cash flow of $26.99M rose 464.2% year over year, ahead of the +382.8% change in trailing-twelve-month investing cash flow. Sequentially, it fell 7.3% from the prior quarter.
Context
- Investing cash flow amounted to 459.5% of revenue in FY2025, up 446.3 pp from a year earlier.
- Investing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +464.2% holds above the trailing-twelve-month pace of +382.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 116.81M USD
- Year-over-year change
- +520.2%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116.81M | +520.2% |
| FY2024 | 2024-12-31 | (27.8M) | +79.9% |
| FY2023 | 2023-12-31 | (138.4M) | +6.9% |
| FY2022 | 2022-12-31 | (148.65M) | -3145.6% |
| FY2021 | 2021-12-31 | (4.58M) | — |
Investing Cash Flow vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 investing cash flow of $139.01M is the 2nd largest of the 11 companies compared; the peer median is $10.2M.
- Its year-over-year change of +382.8% is the highest of 11, against a peer median of +28.3%.
- Investing cash flow amounts to 2422.7% of revenue for TRDA, versus a peer median of 37.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.8M | -3115.8% | — | — | |
| LTM Mar 2026 | $139.01M | +382.8% | — | 2422.7% | |
| LTM Mar 2026 | $132.92M | +56.5% | — | — | |
| LTM Mar 2026 | $92.35M | +117.8% | — | 253.0% | |
| LTM Mar 2026 | $81.05M | -2.1% | — | — | |
| LTM Mar 2026 | $71.19M | +59.3% | +23.9% | 32.7% | |
| LTM Mar 2026 | $59.8M | +0.1% | -3.4% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $11.36M | +118.5% | — | — |
| LTM Mar 2026 | $9.03M | +188.3% | — | — | |
| LTM Mar 2026 | $831K | -41.0% | — | 41.2% | |
| LTM Mar 2026 | $59.66K | -89.1% | -69.0% | 0.1% | |
| Peer median (excluding TRDA) | $10.2M | +28.3% | -3.4% | 37.0% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.